$asnd
Ascendis Pharma sees a surge in social media buzz with over [-----] engagements in [--] hours, primarily driven by X. The company's recent activity is generating significant online discussion.
About $asnd
Ascendis Pharma is a biopharmaceutical company.
Engagements: [-----] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [------]
[--] Month: [-------] -64%
[--] Months: [---------] +126%
[--] Year: [---------] +98%
1-Year High: [-------] on 2025-11-07
1-Year Low: [---] on 2025-11-02
Engagements by network (24h): Reddit: [--] X: [-----]
Mentions: [--] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [--]
1-Year High: [---] on 2025-11-22
1-Year Low: [--] on 2025-09-19
Mentions by network (24h): Reddit: [--] X: [--]
Creators: [--] (24h)
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning $asnd in the last [--] hours which is down 29% from [--] in the previous [--] hours
Daily Average: [--]
1-Year High: [---] on 2025-06-29
1-Year Low: [--] on 2025-09-14
The most influential creators that mention $asnd in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @BiopharmIQ | [--] | [------] | [--] | [-----] |
| @PersimmonTI | [--] | [------] | [--] | [---] |
| @seedy19tron | [--] | [------] | [--] | [---] |
| @tallnfat | [--] | [-----] | [--] | [---] |
| @eWhispers | [--] | [-------] | [--] | [--] |
| @Agent0088156721 | [--] | [---] | [--] | [--] |
| @DwightS2025 | [--] | [---] | [--] | [--] |
| @BioPharmaDive | [--] | [------] | [--] | [--] |
| @PaulaTo43572189 | [--] | [---] | [--] | [--] |
| @BentheFidler | [--] | [-----] | [--] | [--] |
Sentiment: 67%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 67%
Daily Average: 72%
[--] Month: 60% -13%
[--] Months: 60% +14%
[--] Year: 60% -24%
1-Year High: 100% on 2025-02-21
1-Year Low: 20% on 2025-09-28
Most Supportive Themes:
- FDA Decisions in February: (50%) Ascendis Pharma is a biopharmaceutical company.
- PDUFA Calendar for February: (50%) Ascendis Pharma is a biopharmaceutical company.
Most Critical Themes:
Top $asnd Social Posts
Top posts by engagements in the last [--] hours
Showing a maximum of [--] top social posts without a LunarCrush subscription.
"EcoR1 Capital 🔔 🐳 Q4 25* Holdings Released Holdings: [--] Holdings in Top 20: 97.47% Qtr over Qtr Change**: 5.77% 📌 Top Holdings: $ZYME (27.0%) $ANAB (17.0%) $JAZZ (13.0%) $CRNX (9.1%) $CNTA (3.5%) $CRSP (3.3%) $MBX (3.0%) $IMNM (2.8%) $ORIC (2.5%) $GLPG (2.5%) $XNCR (2.3%) $BBOT (1.6%) $ETON (1.6%) $CGON (1.5%) $ZBIO (1.3%) $NGNE (1.2%) $GPCR (1.1%) $PCVX (0.9%) $AQST (0.8%) $VYGR (0.7%) *Holdings as of 12/31/25 in SEC form 13F *Change in value of public company shares held See image for more details 👇 Avoro Capital 🔔 🐳 Q4 25 Holdings Released Holdings: [--] Holdings in Top 20: 94.68%"
X Link @BiopharmIQ 2026-02-17T17:32Z 28.9K followers, [----] engagements
"Avoro Capital 🔔 🐳 Q4 25* Holdings Released Holdings: [--] Holdings in Top 20: 94.68% Qtr over Qtr Change**: 31.51% Top Holdings: $UTHR (13%) $ASND (11%) $MDGL (10%) $ARGX (8.20%) $KRYS (7.00%) $ARWR (6.90%) $KYMR (5.70%) $GPCR (4.50%) $RNA (3.90%) $CNTA (3.60%) $CELC (3.00%) $APLS (3.00%) $VERA (2.90%) $XBI (2.50%) $XENE (2.40%) $TERN (1.70%) $RVMD (1.70%) $QURE (1.40%) $SLNO (1.30%) $OCUL (1.30%) *Holdings as of 12/31/25 in SEC form 13F **Change in value of public company shares held See image for more details 👇 🚨 Hedge Fund Q4 Holdings (13F) data is due today Stay tuned for updates well"
X Link @BiopharmIQ 2026-02-17T16:35Z 28.9K followers, [----] engagements
"@seahorse_anton Nobody is closely following their Skytrofa performance. Yorvipath and CNP launch Sure $asnd"
X Link @tallnfat 2026-02-17T00:50Z [----] followers, [---] engagements
"🔬 Top Biotech Stories $ASND (Ascendis Pharma): Trending as a "growth stock to watch" tomorrow. Investors are closely monitoring their SKYTROFA performance and the expansion of their rare disease pipeline. $VRTX (Vertex Pharmaceuticals): Momentum is building as they ramp up the commercialization of Casgevy (the first CRISPR gene-editing therapy). Analysts have set high price targets (up to $571) citing their dominance in cystic fibrosis and kidney disease. $MLNK (MoonLake Immunotherapeutics): Still riding high after the FDA recently granted Fast Track designation for Sonelokimab. This has"
X Link @seahorse_anton 2026-02-16T23:11Z [---] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing